

Reference number(s)
7315-H

Specialty Quantity Limit Voyxact

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Voyxact	sibeprenlimab-szsi

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for treatment of primary immunoglobulin A nephropathy (IgAN) fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Voyxact (sibeprenlimab-szsi) 400 mg per 2 mL prefilled syringe for subcutaneous injection	1 prefilled syringe per 28 days

FDA-recommended Dosing

400 mg administered by subcutaneous injection once every 4 weeks.

Reference number(s)
7315-H

Reference

1. Voyxact [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Company, Ltd.; November 2025.